Axogen, Inc. (AXGN) FY2025 10-K Annual Report
Axogen, Inc. (AXGN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Axogen, Inc. FY2025 10-K Analysis
Business Overview
- • Core business: Development and commercialization of innovative peripheral nerve regeneration and repair technologies
- • New product: FDA-approved Avance® acellular nerve scaffold (December 3, 2025), launching Q2 2026, replacing Avance® Nerve Graft
- • Strategic shift: Transition of Avance Products from Section 361 human tissue to licensed biologic under Section 351 with post-marketing study commitments
- • Quantitative highlight: Avance Nerve Graft with 17+ years clinical use and over 120,000 implants, US peripheral nerve injury TAM estimated at >$5.6 billion
- • Noteworthy fact: Launch of Avive+ Soft Tissue Matrix in June 2024, an amniotic membrane allograft under FDA HCT/P regulations subject to future oversight changes
Management Discussion & Analysis
- • Revenue $225.2M, up 20.2% YoY from $187.3M driven by unit volume, price, and product mix changes
- • Gross margin 74.3% vs 75.8% YoY, gross profit $167.4M up 17.9% from $142.0M, impacted by $1.9M one-time FDA BLA costs
- • Sales & marketing best performer: $97.7M (+24.6%), R&D $32.9M (+18.4%), G&A $44.6M (+14.2%)
- • Cash, cash equivalents, restricted cash, and investments $45.5M up $6.0M YoY; $133.3M net proceeds from Jan 2026 equity raise, $69.7M used to repay term loan
- • 2026 outlook positive: new Level 3 nerve procedure code boosts reimbursement 35-40%, expanded insurance coverage to 19.8M lives, FDA approval dependency noted as key risk
Risk Factors
- • Regulatory risk: FDA accelerated approval of Avance Products contingent on confirmatory trials with milestones through 2031; failure may cause withdrawal or restrictions
- • Operational risk: Avance manufacturing relies on variable donated cadaveric tissue, causing potential lot failures, product recalls, and supply shortages
- • Geopolitical/macroeconomic risk: Healthcare reimbursement uncertainty; CMS reimbursement changes in 2026 increased outpatient nerve repair payments by 96%-221%, impacting commercial payor coverage
- • Competitive risk: Market acceptance dependent on overcoming surgeon concerns of allograft disease transmission and competing surgical techniques
- • Financial risk: Dependence on six products, with Avance generating ~60% revenue; disruption in Avance sales could materially impact financials
Axogen, Inc. FY2025 Key Financial MetricsXBRL
Revenue
$225M
▲ +20.2% YoY
Net Income
-$16M
▼ -57.6% YoY
Gross Margin
74.3%
▼ -148bp YoY
Operating Margin
-3.5%
▼ -173bp YoY
Net Margin
-7.0%
▼ -165bp YoY
ROE
-12.2%
▼ -260bp YoY
Total Assets
$222M
▲ +8.8% YoY
EPS (Diluted)
$-0.34
▼ -47.8% YoY
Operating Cash Flow
$812,000
▼ -82.1% YoY
Source: XBRL data from Axogen, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Axogen, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.